14 results
8-K
EX-99.2
PRLD
Prelude Therapeutics Inc
12 Nov 21
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
7:57am
in Cmax and AUC Dose-Dependent Inhibition of Serum sDMA Intron Retention Observed at Higher Dose Levels 45 mg/5x week selected as recommended Phase 2 dose … Increases in Cmax and AUC Dose-dependent Inhibition of Serum sDMA Intron Retention Observed at Higher Dose Levels Data presented at 2021 AACR-NCI
8-K
PRLD
Prelude Therapeutics Inc
12 Nov 21
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
7:57am
-time cash bonus (the “Retention Bonus”) to Deborah Morosini, the Company’s Executive Vice President and Chief of Clinical Affairs, in the amount
S-1
EX-10.1
PRLD
Prelude Therapeutics Inc
4 Sep 20
IPO registration
4:48pm
not be unreasonably withheld) of counsel designated by the Company and the retention of such counsel by the Company, the Company will not be liable
8-K
EX-1.1
w58hp otijogigw2
19 May 23
Prelude Therapeutics Announces Launch of Proposed Public Offering
4:06pm
PRE 14A
8rruq3cr1z8p
18 Apr 23
Preliminary proxy
4:00pm
S-3
EX-4.5
bt4u6ml
12 Nov 21
Shelf registration
4:02pm
- Prev
- 1
- Next